Please assess the completion status of the following clinical trial:

Trial Title: Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of good general health aged 18 - 35 years~* Not at risk of pregnancy~* Regular menstrual cycles of 24-35 days duration~* Not pregnant~* Intact uterus and ovaries~* Haemoglobin ≥ 11 g/dl~* Normal laboratory tests and normal TSH~* Willing to abstain from any use of hormonal contraception until study completion~* No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since termination of previous hormonal contraception~* Had at least one complete menstrual cycle (2 menses) following delivery, miscarriage or induced abortion~* Able to give voluntary, written informed consent, and agreeing to observe all study requirements for 5 complete menstrual cycles~Exclusion Criteria:~* Current participation in any other trial of an investigational medicine~* Known hypersensitivity to the ingredients of the test active substances or excipients~* Suspected hyperplasia or carcinoma of the endometrium~* Current pregnancy as confirmed by positive serum beta-hCG at screening~* Desire to get pregnant before the planned end of the study participation~* Currently breastfeeding~* Abnormal Pap smear~* Cancer (past history of any carcinoma or sarcoma)~* Known or suspected alcoholism or drug abuse~* Abnormal thyroid status~* Body mass index \> 32~* Current use of hormonal contraception~* Use of hormonal emergency contraception since last menstrual period~* Severe asthma insufficiently controlled by oral glucocorticoids~* Hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- CDB-2914 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).